Trials / Completed
CompletedNCT03993639
KRN125 for Mobilization of Hematopoietic Stem Cells
A Phase II Clinical Trial of KRN125 to Mobilize Hematopoietic Stem Cells Into Peripheral Blood in Healthy Volunteers
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 35 (actual)
- Sponsor
- Kyowa Kirin Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
Data collection to evaluate safety and effect of hematopoietic stem cell mobilization into the peripheral blood after a single subcutaneous (SC) dose of KRN125(Pegfilgrastim)in healthy adults.
Detailed description
KRN125 is administered as a single SC dose to the Day 1. The stem cell mobilization protocols will be monitored for safety and efficacy during the mobilization period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pegfilgrastim | Single dose of SC administration |
Timeline
- Start date
- 2019-05-28
- Primary completion
- 2020-07-21
- Completion
- 2020-08-28
- First posted
- 2019-06-21
- Last updated
- 2021-01-22
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT03993639. Inclusion in this directory is not an endorsement.